Menu
Search
|

Menu

Close
X

Cymabay Therapeutics Inc CBAY.OQ (NASDAQ Stock Exchange Global Select Market)

6.40 USD
+0.00 (+0.00%)
As of Jul 23
Previous Close 6.40
Open 6.50
Volume 179,677
3m Avg Volume 317,910
Today’s High 6.50
Today’s Low 6.23
52 Week High 14.00
52 Week Low 4.82
Shares Outstanding (mil) 43.76
Market Capitalization (mil) 358.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.64 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
10
FY16
0
EPS (USD)
FY19
-0.373
FY18
-1.255
FY17
-0.832
FY16
-1.137
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
74.86
7.92
Price to Book (MRQ)
vs sector
110.22
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
350.44
14.56
LT Debt to Equity (MRQ)
vs sector
215.01
10.21
Return on Investment (TTM)
vs sector
-182.71
14.49
Return on Equity (TTM)
vs sector
-308.78
15.79

EXECUTIVE LEADERSHIP

Robert Wills
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sujal Shah
President, Chief Executive Officer, Director, Since 2017
Salary: $451,796.00
Bonus: $271,078.00
Charles McWherter
Senior Vice President, Chief Scientific Officer, Since
Salary: $405,418.00
Bonus: $170,276.00
Daniel Menold
Vice President - Finance, Since 2017
Salary: $257,290.00
Bonus: $92,624.00
Paul Quinlan
General Counsel, Corporate Secretary, Since 2017
Salary: $375,863.00
Bonus: $157,862.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7575 Gateway Blvd Ste 110
NEWARK   CA   94560-1194

Phone: +1510.2938800

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

SPONSORED STORIES